GSK: Jefferies says stock 'offers compelling value'

(CercleFinance.com) - The analyst still believes that GSK's "current share price offers compelling value" ahead of the 18 July Haleon consumer spin.

Jefferies therefore reiterates its buy rating on the stock, along with a target price of 2100p (current price 1680p, -2.2%).

"The at least +6% sales and +12%-14% EPS CAGR of New GSK is underappreciated, as the #2 growth profile in EU large-caps," Jefferies said.

"We accept New GSK pipeline remains a work-in-progress, but catalysts are starting to emerge, and the Vaccines franchise just keeps getting better," analysts add.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.